PARADIGM-HF · 2014 · New England Journal of Medicine
Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
Sacubitril/valsartan (ARNI) reduces CV death and HF hospitalization vs.
Source publication
Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
John J.V. McMurray et al. · New England Journal of Medicine · 2014
Sponsor
Novartis Pharmaceuticals
Principal investigator
Novartis Pharmaceuticals
Population
Heart Failure With Reduced Ejection Fraction; n=8442
Primary endpoint
Number of Participants That Had First Occurrence of the Composite Endpoint, Which is Defined as Either Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization
Methodology notes
Full methodology is under curation. This project aggregates 3 seeded claims across three temporal layers. The replication spec, pre-registered analysis, and version history will appear here as the project matures.
Funding progress
$2.3M / $3.6M
65%
Funding displayed here is indicative of collaborator interest. Sciync does not broker money, grants, or securities.
Temporal layers
Published findings under validation
1
Active replication in progress
1
Forecast horizons pending resolution
1